Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOQVU9)

• Drug Name: Hydroxyurea Drug Info
• Synonyms: Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA

Indication

Disease Entry	ICD 11	Status	REF
Chronic myelogenous leukaemia	2A20.0	Approved	[1]
Desmoid tumour	2F7C	Approved	[2]
Fibromatosis		Approved	[2]
Head and neck cancer	2D42	Approved	[2]
Melanoma	2C30	Approved	[2]
Pulmonary hypertension	BB01	Approved	[2]
Sickle-cell anaemia	3A51	Approved	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 3657
  ChEBI ID: CHEMBL467
  CAS Number: CAS 127-07-1
  TTD Drug ID: DMOQVU9
  VARIDT Drug ID: DR01177
  ACDINA Drug ID: D00317

Molecule-Related Drug Atlas

Drug(s) Targeting Ribonucleoside-diphosphate reductase M2 (RRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[3]
CO-101	DMH5GQU	Pancreatic cancer	2C10	Phase 2	[12]
Triapine	DM7XZY5	Nerve injury	ND56.4	Phase 2	[13]
CALAA-01	DMT4Z5B	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
LY-2334737	DMCBV20	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
Gallium maltolate	DMX0Z51	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[16]
MDL 101,731	DMKEYSX	Gastric adenocarcinoma	2B72	Discontinued in Phase 2	[17]
NKP-46	DMK8UD0	Solid tumour/cancer	2A00-2F9Z	Preclinical	[18]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[19]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[20]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[5]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[21]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[5]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[5]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[22]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[5]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[23]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[24]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[25]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[26]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[27]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[28]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[27]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[29]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[30]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[31]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[32]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[29]

Drug(s) Transported By Organic anion transporting polypeptide 1A2 (SLCO1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[33]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[34]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[35]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[36]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[37]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[38]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[39]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[40]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[41]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[42]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[27]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[44]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[45]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[27]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[46]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[30]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[32]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[47]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[32]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[48]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[49]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[50]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[51]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[53]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[54]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[54]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[55]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[56]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[57]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[58]
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[59]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[60]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[61]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[62]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[60]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[63]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]

Drug(s) Affected By Solute carrier organic anion transporter family member 1A2 (SLCO1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[59]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[39]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[63]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[68]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[69]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[70]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[71]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[72]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[73]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[74]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[75]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[76]
Selenium	DM25CGV	N. A.	N. A.	Approved	[77]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[78]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[78]

Drug(s) Affected By TP53-regulated inhibitor of apoptosis 1 (TRIAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[84]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[84]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[86]

Drug(s) Affected By Heat shock cognate 71 kDa protein (HSPA8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[87]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[88]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[91]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[92]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[93]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[94]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[95]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[96]

Drug(s) Affected By Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[97]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[88]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[98]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[99]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[100]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[101]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[104]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[105]

Drug(s) Affected By Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[106]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[107]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[107]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[84]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[110]

Drug(s) Affected By DNA damage-binding protein 2 (DDB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[112]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[84]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]

Drug(s) Affected By Transcription factor E2F8 (E2F8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[115]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[116]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[117]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[119]

Drug(s) Affected By Transmembrane protein 250 (TMEM250)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[7]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[120]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[121]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[122]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[7]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[123]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[124]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[125]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM38 (TRIM38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[126]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[129]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[130]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[63]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]

Drug(s) Affected By Serine/threonine-protein kinase Chk1 (CHEK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[132]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[133]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[134]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[135]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[137]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[138]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[139]

Drug(s) Affected By Transcription factor EC (TFEC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[140]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[141]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[124]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[142]

Drug(s) Affected By E3 ubiquitin-protein ligase RNF113A (RNF113A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[143]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]

Drug(s) Affected By DNA repair protein RAD51 homolog 3 (RAD51C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[144]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[11]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]

Drug(s) Affected By Protein regulator of cytokinesis 1 (PRC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[146]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[10]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[84]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]

Drug(s) Affected By HMG box-containing protein 1 (HBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[115]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[148]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]

Drug(s) Affected By Kinesin-like protein KIF20A (KIF20A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]

Drug(s) Affected By Myelin protein zero-like protein 1 (MPZL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[143]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[150]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]

Drug(s) Affected By Serine/threonine-protein kinase Chk2 (CHEK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[151]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[152]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[137]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[153]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[154]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[155]

Drug(s) Affected By Cystatin-A (CSTA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[156]
Selenium	DM25CGV	N. A.	N. A.	Approved	[126]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[157]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[93]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[158]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[159]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]

Drug(s) Affected By Endothelin-3 (EDN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[71]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[160]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[161]
ACYLINE	DM9GRTK	Prostate cancer	2C82.0	Phase 2	[162]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[163]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[123]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[164]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[165]
Selenium	DM25CGV	N. A.	N. A.	Approved	[126]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[166]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[167]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[168]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[169]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[170]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[171]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[172]

Drug(s) Affected By Nuclear factor NF-kappa-B p105 subunit (NFKB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[173]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[174]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[88]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[98]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[175]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[176]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[177]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[178]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[179]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[134]

Drug(s) Affected By Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[180]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[116]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[181]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 6 (FAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[182]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[132]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[183]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[184]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[185]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[186]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[187]
Fructose	DM43AN2	Vomiting	MD90	Approved	[188]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[158]

Drug(s) Affected By G1/S-specific cyclin-D2 (CCND2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Selenium	DM25CGV	N. A.	N. A.	Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[106]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[190]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[191]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[193]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[195]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]

Drug(s) Affected By G1/S-specific cyclin-D3 (CCND3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[196]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[190]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[197]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[198]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[199]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[174]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]

Drug(s) Affected By Sodium-dependent serotonin transporter (SLC6A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[200]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[201]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[202]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[203]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[204]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[205]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[203]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]

Drug(s) Affected By Cyclin-dependent kinases regulatory subunit 2 (CKS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[126]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[199]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[206]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[67]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[193]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[207]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[208]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[209]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[210]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[132]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[211]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[212]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[213]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 2A (CDKN2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[212]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[214]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[134]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[215]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[216]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[217]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[218]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[219]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[220]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[196]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[212]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[221]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[222]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[223]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[224]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[225]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[226]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[227]

Drug(s) Affected By Neurogenic locus notch homolog protein 1 (NOTCH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[228]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[229]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[230]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[231]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[232]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[234]

Drug(s) Affected By LIM/homeobox protein Lhx2 (LHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[235]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]

Drug(s) Affected By Max-interacting protein 1 (MXI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[236]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[84]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[84]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[119]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[237]

Drug(s) Affected By Cyclin-G1 (CCNG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[106]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[238]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[239]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[206]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[240]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[111]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[160]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[241]

Drug(s) Affected By Importin subunit alpha-1 (KPNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[242]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[243]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[244]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[245]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]

Drug(s) Affected By DNA mismatch repair protein Msh6 (MSH6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[239]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[119]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]

Drug(s) Affected By Serine/threonine-protein kinase PLK1 (PLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[132]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[246]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[247]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]

Drug(s) Affected By RecQ-like DNA helicase BLM (BLM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]

Drug(s) Affected By Ataxin-1 (ATXN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[124]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[248]
Selenium	DM25CGV	N. A.	N. A.	Approved	[126]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[249]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[84]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[84]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]

Drug(s) Affected By Ras-related protein Rap-2b (RAP2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[250]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[251]

Drug(s) Affected By Protein BTG2 (BTG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[132]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[239]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[252]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[253]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[199]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[254]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[255]

Drug(s) Affected By Transcription factor E2F1 (E2F1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[256]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[257]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[258]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[259]
Selenium	DM25CGV	N. A.	N. A.	Approved	[126]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[260]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[261]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]

Drug(s) Affected By Histone-lysine N-methyltransferase MECOM (MECOM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[129]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[63]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[262]

Drug(s) Affected By Unconventional myosin-Ie (MYO1E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[7]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[7]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[263]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[264]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM32 (TRIM32)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[264]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[251]

Drug(s) Affected By Serine-protein kinase ATM (ATM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[265]
Paromomycin	DM1AGXN	Amoebiasis	1A36	Approved	[266]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[267]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[211]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[186]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[115]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[268]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[148]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[269]

Drug(s) Affected By Oligodendrocyte transcription factor 2 (OLIG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[203]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[270]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[235]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[235]
Sulfadiazine	DMTW3R8	Rheumatic fever	1B40-1B42	Approved	[203]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[203]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[71]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[161]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[123]
Glyphosate	DM0AFY7	Malaria	1F40-1F45	Investigative	[203]

Drug(s) Affected By Protein BTG3 (BTG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[199]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[271]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[272]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[120]

Drug(s) Affected By Histone RNA hairpin-binding protein (SLBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[124]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[273]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]

Drug(s) Affected By Cyclin-dependent kinase 5 activator 1 (CDK5R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[87]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[274]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[7]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[275]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[276]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[277]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[276]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[129]

Drug(s) Affected By Neutral amino acid transporter B(0) (SLC1A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[84]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[84]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[84]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]

Drug(s) Affected By Flap endonuclease GEN homolog 1 (GEN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[278]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[279]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[264]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[280]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[251]

Drug(s) Affected By Proline/serine-rich coiled-coil protein 1 (PSRC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[254]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[161]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[245]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[281]

Drug(s) Affected By Protein aurora borealis (BORA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[207]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[115]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[254]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[195]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[245]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[278]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[273]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]

Drug(s) Affected By Leucine-rich repeat-containing protein 47 (LRRC47)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[282]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[122]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[126]

Drug(s) Affected By Lipase member H (LIPH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[195]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[270]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[7]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[263]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[283]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[241]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[284]

Drug(s) Affected By Cytochrome c oxidase assembly factor 7 (COA7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[121]

Drug(s) Affected By Mitochondrial potassium channel (CCDC51)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[121]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[109]

Drug(s) Affected By Integrator complex subunit 15 (INTS15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[126]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[251]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[126]

Drug(s) Affected By Small integral membrane protein 14 (SMIM14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[7]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[7]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[80]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[237]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]

Drug(s) Affected By Protein pelota homolog (PELO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[285]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[286]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]

Drug(s) Affected By TIMELESS-interacting protein (TIPIN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[278]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]

Drug(s) Affected By tRNA pseudouridine(38/39) synthase (PUS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]

Drug(s) Affected By Transmembrane protein 185B (TMEM185B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[264]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[277]

Drug(s) Affected By Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]
Indomethacin	DMSC4A7	Bursitis		Approved	[287]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[111]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[277]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[122]
Adenine	DMZLHKJ	Malnutrition	5B50-5B71	Approved	[6]

Drug(s) Affected By GrpE protein homolog 1, mitochondrial (GRPEL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[288]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[116]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]

Drug(s) Affected By Protein CLN8 (CLN8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[124]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[289]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[110]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[263]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[250]

Drug(s) Affected By Inactive cell surface hyaluronidase CEMIP2 (CEMIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[149]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[290]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[7]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[279]

Drug(s) Affected By rRNA methyltransferase 2, mitochondrial (MRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[237]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[6]

Drug(s) Affected By ERBB receptor feedback inhibitor 1 (ERRFI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[257]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]

Drug(s) Affected By Frizzled-1 (FZD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[63]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[6]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[291]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]

Drug(s) Affected By RING finger protein 24 (RNF24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[7]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[292]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[71]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[120]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[121]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[122]

Drug(s) Affected By DNA polymerase eta (POLH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[248]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[249]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[270]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[119]
Lomustine	DMMWSUL	Brain cancer	2A00	Approved	[293]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]

Drug(s) Affected By 5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[84]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[119]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[294]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[6]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]

Drug(s) Affected By V-type proton ATPase 116 kDa subunit a 2 (ATP6V0A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[239]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[129]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[233]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[277]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[296]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[239]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[129]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[123]

Drug(s) Affected By Pleckstrin homology-like domain family A member 3 (PHLDA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[82]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[84]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[119]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[84]

Drug(s) Affected By Sestrin-1 (SESN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[297]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[153]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[254]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[206]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[113]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[84]

Drug(s) Affected By Solute carrier family 22 member 4 (SLC22A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[282]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[298]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[262]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[299]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[300]

Drug(s) Affected By Organic cation/carnitine transporter 2 (SLC22A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[301]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[302]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[298]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[109]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[127]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[300]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[303]

Drug(s) Affected By Protein artemis (DCLRE1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[147]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[108]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[85]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[264]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[71]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[304]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[304]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[251]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[109]

Drug(s) Affected By Urea transporter 2 (SLC14A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[292]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[305]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[123]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[124]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ribonucleoside-diphosphate reductase M2 (RRM2)	TTBWDI0	RIR2_HUMAN	Modulator	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[4]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[4]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[4]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Gene/Protein Processing	[6]
Ataxin-1 (ATXN1)	OTQF0HNR	ATX1_HUMAN	Gene/Protein Processing	[6]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Gene/Protein Processing	[6]
Cyclin-dependent kinase 5 activator 1 (CDK5R1)	OTJELWK0	CD5R1_HUMAN	Gene/Protein Processing	[7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[8]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Gene/Protein Processing	[9]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Gene/Protein Processing	[9]
Cyclin-dependent kinases regulatory subunit 2 (CKS2)	OTPTMHIV	CKS2_HUMAN	Gene/Protein Processing	[10]
Cyclin-G1 (CCNG1)	OT17IA9L	CCNG1_HUMAN	Gene/Protein Processing	[8]
Cystatin-A (CSTA)	OT1K68KE	CYTA_HUMAN	Gene/Protein Processing	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6822).
• [2] Hydroxyurea FDA Label
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [5] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [6] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [7] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [8] Hydroxyurea (HU)-induced apoptosis in the mouse fetal lung. Exp Mol Pathol. 2005 Aug;79(1):59-67. doi: 10.1016/j.yexmp.2005.02.007. Epub 2005 Apr 22.
• [9] Hydroxyurea induces a senescence-like change of K562 human erythroleukemia cell. J Cancer Res Clin Oncol. 2000 Aug;126(8):455-60.
• [10] Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
• [11] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [12] Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
• [13] PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
• [14] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [15] Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
• [16] Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1739-43.
• [17] Tezacitabine Hoechst Marion Roussel.Curr Opin Investig Drugs.2000 Sep;1(1):135-40.
• [18] Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. J Clin Oncol (Meeting Abstracts) June 2005 vol. 23 no. 16_suppl 3205.
• [19] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [20] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [21] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [22] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [23] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [24] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [25] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [26] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [27] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [28] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [29] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [30] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [31] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [32] FDA Drug Development and Drug Interactions
• [33] Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
• [34] Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
• [35] Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
• [36] Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
• [37] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [38] Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
• [39] Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
• [40] Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
• [41] Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
• [42] Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
• [43] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [44] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [45] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [46] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [47] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [48] Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
• [49] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [50] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [51] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [52] SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
• [53] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [54] Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
• [55] Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.
• [56] Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
• [57] Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. doi: 10.1038/s41598-017-17731-1.
• [58] Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
• [59] Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
• [60] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [61] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [62] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [63] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [64] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [65] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [66] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [67] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [68] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [69] The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol Pharmacol. 2012 Jul;82(1):37-46. doi: 10.1124/mol.112.077909. Epub 2012 Apr 3.
• [70] UDCA and CDCA alleviate 17-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. doi: 10.1016/j.taap.2016.10.011. Epub 2016 Oct 12.
• [71] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [72] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [73] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [74] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [75] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [76] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [77] Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther. 2002 May-Jun;1(3):287-90. doi: 10.4161/cbt.83.
• [78] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [79] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [80] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [81] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [82] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [83] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [84] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [85] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [86] Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
• [87] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [88] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [89] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [90] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [91] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [92] Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
• [93] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [94] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [95] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [96] Indomethacin and ibuprofen induce Hsc70 nuclear localization and activation of the heat shock response in HeLa cells. Biochem Biophys Res Commun. 2004 Jan 23;313(4):863-70. doi: 10.1016/j.bbrc.2003.12.018.
• [97] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [98] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [99] Chromium III histidinate exposure modulates gene expression in HaCaT human keratinocytes exposed to oxidative stress. Biol Trace Elem Res. 2010 Oct;137(1):23-39.
• [100] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [101] A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate. Cancer Gene Ther. 2008 Sep;15(9):576-90. doi: 10.1038/cgt.2008.28. Epub 2008 May 16.
• [102] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [103] Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
• [104] The Effect of GADD45a on Furazolidone-Induced S-Phase Cell-Cycle Arrest in Human Hepatoma G2 Cells. J Biochem Mol Toxicol. 2015 Oct;29(10):489-495. doi: 10.1002/jbt.21719. Epub 2015 Jun 11.
• [105] Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene. 2004 Jun 3;23(26):4614-23. doi: 10.1038/sj.onc.1207598.
• [106] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [107] Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
• [108] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [109] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [110] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [111] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [112] Evaluation of gene expression changes in human primary lung epithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites and to arsenic trioxide. Environ Mol Mutagen. 2015 Jun;56(5):477-90. doi: 10.1002/em.21937. Epub 2015 Apr 14.
• [113] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [114] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [115] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [116] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [117] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [118] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [119] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [120] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [121] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [122] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [123] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [124] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [125] Gene expression profile analysis of gallic acid-induced cell death process. Sci Rep. 2021 Aug 18;11(1):16743. doi: 10.1038/s41598-021-96174-1.
• [126] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [127] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [128] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [129] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [130] Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood. 2005 Feb 1;105(3):1214-21. doi: 10.1182/blood-2004-03-1182. Epub 2004 Sep 28.
• [131] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [132] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [133] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [134] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [135] Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: modulation of curcumin. Toxicol Mech Methods. 2017 Mar;27(3):165-172. doi: 10.1080/15376516.2016.1273424. Epub 2017 Jan 8.
• [136] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [137] Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci. 2009 Sep;111(1):120-30. doi: 10.1093/toxsci/kfp136. Epub 2009 Jun 18.
• [138] ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem. 2006 Sep 29;281(39):28764-71. doi: 10.1074/jbc.M604392200. Epub 2006 Aug 3.
• [139] Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem. 2012 Apr 20;287(17):14289-300. doi: 10.1074/jbc.M112.353201. Epub 2012 Mar 1.
• [140] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [141] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [142] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [143] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [144] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [145] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [146] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [147] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [148] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [149] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [150] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [151] Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One. 2011;6(12):e28862. doi: 10.1371/journal.pone.0028862. Epub 2011 Dec 15.
• [152] Direct activation of ATM by resveratrol under oxidizing conditions. PLoS One. 2014 Jun 16;9(6):e97969. doi: 10.1371/journal.pone.0097969. eCollection 2014.
• [153] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [154] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [155] Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009 Aug;30(8):1320-9. doi: 10.1093/carcin/bgp138. Epub 2009 Jun 5.
• [156] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [157] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [158] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [159] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [160] Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci. 2001 Jan;59(1):185-92.
• [161] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [162] Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007 May 15;67(10):5033-41.
• [163] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [164] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [165] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [166] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [167] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [168] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [169] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [170] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [171] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [172] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [173] Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
• [174] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [175] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [176] The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res. 2008 Oct 15;68(20):8269-77. doi: 10.1158/0008-5472.CAN-08-2010.
• [177] Development of an alternative zebrafish model for drug-induced intestinal toxicity. J Appl Toxicol. 2018 Feb;38(2):259-273. doi: 10.1002/jat.3520. Epub 2017 Oct 13.
• [178] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [179] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [180] Activation of the constitutive androstane receptor by monophthalates. Chem Res Toxicol. 2016 Oct 17;29(10):1651-1661.
• [181] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [182] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [183] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [184] Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006 Dec;387(12):1629-33. doi: 10.1515/BC.2006.203.
• [185] Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
• [186] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [187] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [188] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [189] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [190] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [191] Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther. 2003 Jun;305(3):932-42. doi: 10.1124/jpet.103.049098. Epub 2003 Mar 20.
• [192] Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res. 2005 Jul 15;65(14):6476-83. doi: 10.1158/0008-5472.CAN-05-0370.
• [193] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [194] 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct. 2005;30(1):1-6. doi: 10.1247/csf.30.1.
• [195] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [196] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [197] Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. J Appl Toxicol. 2013 Dec;33(12):1500-5. doi: 10.1002/jat.2829. Epub 2012 Oct 30.
• [198] Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
• [199] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [200] Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005 Nov 25;389(1):12-6. doi: 10.1016/j.neulet.2005.06.048.
• [201] Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. doi: 10.1017/S1461145703003663.
• [202] Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15. doi: 10.1111/j.1365-3083.2005.01715.x.
• [203] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [204] Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
• [205] Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. J Med Chem. 2011 Sep 22;54(18):6305-18. doi: 10.1021/jm200682b. Epub 2011 Aug 23.
• [206] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [207] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [208] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [209] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [210] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [211] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [212] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [213] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [214] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [215] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [216] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [217] [Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai Zheng. 2004 Jun;23(6):626-30.
• [218] p16 loss facilitate hydroquinone-induced malignant transformation of TK6 cells through promoting cell proliferation and accelerating the cell cycle progression. Environ Toxicol. 2021 Aug;36(8):1591-1599. doi: 10.1002/tox.23155. Epub 2021 May 1.
• [219] Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 2008;47(6):1062-70.
• [220] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [221] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [222] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [223] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [224] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [225] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [226] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [227] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [228] Quercetin attenuates cell apoptosis of oxidant-stressed SK-N-MC cells while suppressing up-regulation of the defensive element, HIF-1alpha. Neuroscience. 2014 Sep 26;277:780-93.
• [229] Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci. 2012;13(8):9627-9641. doi: 10.3390/ijms13089627. Epub 2012 Aug 2.
• [230] Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway. Chem Biol Interact. 2018 Oct 1;294:28-33. doi: 10.1016/j.cbi.2018.08.018. Epub 2018 Aug 18.
• [231] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [232] The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J Cell Biochem. 2009 Mar 1;106(4):682-92. doi: 10.1002/jcb.22065.
• [233] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [234] Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. Toxicol Appl Pharmacol. 2020 Jun 1;396:115001. doi: 10.1016/j.taap.2020.115001. Epub 2020 Apr 8.
• [235] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [236] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [237] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [238] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [239] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [240] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [241] Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006 May 18;5:20. doi: 10.1186/1476-4598-5-20.
• [242] Differentiation-associated alteration in gene expression of importins and exportins in human leukemia HL-60 cells. Biomed Res. 2008 Jun;29(3):141-5. doi: 10.2220/biomedres.29.141.
• [243] DNA microarray analysis of changes in gene expression induced by 1,25-dihydroxyvitamin D3 in human promyelocytic leukemia HL-60 cells. Biomed Res. 2006 Jun;27(3):99-109. doi: 10.2220/biomedres.27.99.
• [244] Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
• [245] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [246] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [247] PLK1 targets NOTCH1 during DNA damage and mitotic progression. J Biol Chem. 2019 Nov 22;294(47):17941-17950. doi: 10.1074/jbc.RA119.009881. Epub 2019 Oct 9.
• [248] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [249] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [250] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [251] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [252] Role of DNA Repair Pathways in Response to Zidovudine-induced DNA Damage in Immortalized Human Liver THLE2 Cells. Int J Biomed Sci. 2013 Mar;9(1):18-25.
• [253] Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
• [254] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [255] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [256] Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med. 2004 Jan;10(1):40-7. doi: 10.1038/nm969. Epub 2003 Dec 14.
• [257] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [258] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [259] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [260] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [261] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [262] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [263] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [264] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [265] Cannabidiol Induces Cell Cycle Arrest and Cell Apoptosis in Human Gastric Cancer SGC-7901 Cells. Biomolecules. 2019 Jul 25;9(8):302. doi: 10.3390/biom9080302.
• [266] Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
• [267] Pro-oxidant induced DNA damage in human lymphoblastoid cells: homeostatic mechanisms of genotoxic tolerance. Toxicol Sci. 2012 Aug;128(2):387-97. doi: 10.1093/toxsci/kfs152. Epub 2012 Apr 26.
• [268] An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
• [269] Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
• [270] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [271] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [272] BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009 Apr;30(4):662-70. doi: 10.1093/carcin/bgp042. Epub 2009 Feb 12.
• [273] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [274] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [275] Systematic transcriptome-based comparison of cellular adaptive stress response activation networks in hepatic stem cell-derived progeny and primary human hepatocytes. Toxicol In Vitro. 2021 Jun;73:105107. doi: 10.1016/j.tiv.2021.105107. Epub 2021 Feb 3.
• [276] Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
• [277] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [278] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [279] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [280] Expression and localization of GEN1 in mouse mammary epithelial cells. J Biochem Mol Toxicol. 2014 Oct;28(10):450-5. doi: 10.1002/jbt.21584. Epub 2014 Jun 30.
• [281] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [282] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [283] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [284] Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
• [285] The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007 Apr;6(4):1300-9.
• [286] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [287] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [288] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [289] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [290] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [291] The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry. 2009 Nov 3;48(43):10267-74. doi: 10.1021/bi9009677.
• [292] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [293] Translesion polymerase is upregulated by cancer therapeutics and confers anticancer drug resistance. Cancer Res. 2014 Oct 1;74(19):5585-96. doi: 10.1158/0008-5472.CAN-14-0953. Epub 2014 Aug 14.
• [294] AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-B pathway. Environ Toxicol. 2016 Jul;31(7):866-76. doi: 10.1002/tox.22097. Epub 2014 Dec 24.
• [295] p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One. 2011 Apr 21;6(4):e19198. doi: 10.1371/journal.pone.0019198.
• [296] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [297] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [298] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [299] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [300] Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
• [301] Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicol Appl Pharmacol. 2019 Jan 15;363:47-56. doi: 10.1016/j.taap.2018.11.007. Epub 2018 Nov 19.
• [302] Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos. 2005 Jan;33(1):31-7. doi: 10.1124/dmd.104.001560. Epub 2004 Oct 14.
• [303] Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant. 2010 Feb;25(2):426-33. doi: 10.1093/ndt/gfp456. Epub 2009 Sep 7.
• [304] Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells. J Radiat Res. 2011;52(4):415-24. doi: 10.1269/jrr.10168.
• [305] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.